Статья

Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort.

N. Papadopoulos, A. Mathioudakis, A. Custovic, A. Deschildre, W. Phipatanakul, G. Wong, P. Xepapadaki, R. Abou-Taam, I. Agache, J. Castro-Rodriguez, Z. Chen, P. Cros, J. Dubus, Z. El-Sayed, R. El-Owaidy, W. Feleszko, V. Fierro, A. Fiocchi, L. Garcia-Marcos, A. Goh, E. Hossny, Y. Villalobos, T. Jartti, P. Roux, J. Levina, A. Garcia, Á. Ramos, M. Almeida, C. Murray, K. Nagaraju, M. Nagaraju, E. Rodriguez, L. Namazova-Baranova, A. Garcia, C. Beltrán, T. Ratchataswan, D. Yeverino, E. Zagal, C. Schweitzer, M. Tulkki, K. Wasilczuk, D. Xu, P. Tank,
2020

ABSTRACT Importance Importance: The interplay between COVID-19 pandemic and asthma in children is still unclear. Objective We evaluated the impact of COVID-19 pandemic on childhood asthma outcomes. Design The PeARL multinational cohort included children with asthma and non-asthmatic controls recruited during the COVID-19 pandemic and compared current disease activity with data available from the previous year. Setting Pediatric outpatient clinics. Participants The study included 1,054 children with asthma and 505 non-asthmatic controls, aged between 4-18 years, from 25 pediatric departments, from 15 countries globally. Exposures COVID-19 pandemic first wave, starting from the date of the first fatality in the respective country. Main outcomes and measures We assessed the pandemic’s impact on the frequency of respiratory infections, emergency presentations and hospital admissions in asthmatic versus non-asthmatic participants, controlling for confounding factors including the pandemic’s duration and the frequency of such acute events during 2019. Using paired analyses, we evaluated the impact of the pandemic on the annualized frequency of asthma attacks and the previously mentioned acute events, asthma control, and pulmonary function in children with asthma, compared to their baseline disease activity, during the preceding year. Results During the pandemic, children with asthma experienced fewer upper respiratory tract infections, episodes of pyrexia, emergency visits, hospital admissions, asthma attacks and hospitalizations due to asthma, in comparison to the preceding year. Sixty-six percent of asthmatic children had improved asthma control while in 33% the improvement exceeded the minimally clinically important difference. Pre-bronchodilatation FEV1 and peak expiratory flow rate were also improved during the pandemic. When compared to non-asthmatic controls, children with asthma were not found to be at increased risk of LRTIs, episodes of pyrexia, emergency visits or hospitalizations during the pandemic. However, an increased risk of URTIs emerged. Conclusions and relevance Childhood asthma outcomes, including control, were improved during the first wave of the COVID-19 pandemic, probably because of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the notion that childhood asthma may be a risk factor for COVID-19. Furthermore, the potential for improving childhood asthma outcomes through environmental control becomes apparent. Key Points Question What was the impact of COVID-19 pandemic on childhood asthma outcomes? Findings During the first wave of the pandemic, children with asthma have experienced improved outcomes, as evidenced by fewer asthma attachks, hospitalizations, improved scores in validated asthma control measures and improved pulmonary function. Meaning This is the first study to show a positive impact of COVID-19 pandemic on childhood asthma activity. This is probably the result of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the hypothesis that childhood asthma may be a risk factor for COVID-19.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2020-10-28

Метаданные

Об авторах
  • N. Papadopoulos
    National and Kapodistrian University of Athens; University of Manchester
  • A. Mathioudakis
    Manchester Academic Health Science Centre; University of Manchester
  • A. Custovic
    Imperial College London
  • A. Deschildre
    Pasteur Institute
  • W. Phipatanakul
    Boston Children's Hospital
  • G. Wong
    The Chinese University of Hong Kong
  • P. Xepapadaki
    National and Kapodistrian University of Athens
  • R. Abou-Taam
    Necker-Enfants Malades Hospital
  • I. Agache
    Transylvania University
  • J. Castro-Rodriguez
    Pontifical Catholic University of Chile
  • Z. Chen
    Zhejiang University
  • P. Cros
    Department of Pediatrics, University Hospital Morvan
  • J. Dubus
    Centre de Ressources et de Compétences pour la Mucoviscidose Pneumo-Allergologie
  • Z. El-Sayed
    Ain Shams University
  • R. El-Owaidy
    Ain Shams University
  • W. Feleszko
    Medical University of Warsaw
  • V. Fierro
    Boston Children's Hospital
  • A. Fiocchi
    Boston Children's Hospital
  • L. Garcia-Marcos
    University of Murcia
  • A. Goh
    Rush Medical College
  • E. Hossny
    Ain Shams University
  • Y. Villalobos
    Mexican Social Security Institute
  • T. Jartti
    Oulu University Hospital
  • P. Roux
    Department of pediatrics, Groupe hospitalier Le Havre
  • J. Levina
    Russian Academy of Sciences
  • A. Garcia
    Allergy and Clinical Immunology Service of the University Hospital of Puebla
  • Á. Ramos
    Boston Children's Hospital
  • M. Almeida
    Allergy Center, CUF Descobertas Hospital
  • C. Murray
    University of Manchester
  • K. Nagaraju
    VN Allergy & Asthma Research Centre
  • M. Nagaraju
    Professor & Head, Department of Allergy & Clinical Immunology, Saveetha Medical College
  • E. Rodriguez
    Pediatric Allergy and Clinical Immunology Service, Hospital Infantil
  • L. Namazova-Baranova
    Russian Academy of Sciences; Russian National Research Medical University
  • A. Garcia
    Boston Children's Hospital
  • C. Beltrán
    Teaching and Research Department and Paediatric Allergy department, Hospital with Specialties Juan María de Salvatierra
  • T. Ratchataswan
    Boston Children's Hospital
  • D. Yeverino
    Allergy and Clinical Immunology Department, Hospital Universitario de Puebla
  • E. Zagal
    Mexican Social Security Institute
  • C. Schweitzer
    CHRU de Nancy, Hôpital d’Enfants, Rue du Morvan
  • M. Tulkki
    Turku University Hospital
  • K. Wasilczuk
    Medical University of Warsaw
  • D. Xu
    Zhejiang University
  • P. Tank
Предметная рубрика
  • COVID-19
Тип документа
  • other
Источник
  • lens